Data / Research funding / Prescription Drug Misuse
Prescription Drug Misuse: 231 NIH awards ($357.3M) to 121 organizations
231 NIH awards ($357.3M) in the NIH spending category Prescription Drug Misuse, to 121 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
231 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Kentucky CAN HEAL (Communities and Networks Helping End Addiction Long-term) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $36,092,167 | April 17, 2019 | March 31, 2025 | WALSH, SHARON L. | reporter.nih.gov |
| Arylepoxamides: A new class of potent, safer analgesics | NIH | National Institute on Drug Abuse | 2021 to 2023 | $13,729,307 | December 15, 2018 | August 31, 2025 | REICH, JEFFREY | reporter.nih.gov |
| PF614-MPAR: clinical development of opioid with oral overdose protection | NIH | National Institute on Drug Abuse | 2024 to 2025 | $9,861,616 | September 1, 2024 | May 31, 2027 | KIRKPATRICK, LYNN | reporter.nih.gov |
| Prevention Research Center: Parenting Among Women Who Are Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2023 | $8,972,150 | August 15, 2019 | May 31, 2025 | LEVE, LESLIE DIANE | reporter.nih.gov |
| Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,654,182 | August 15, 2023 | July 31, 2025 | GRIECO, JOSEPH | reporter.nih.gov |
| Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $6,352,490 | September 21, 2020 | August 31, 2025 | DOORENBOS, ARDITH Z | reporter.nih.gov |
| PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,585,570 | September 15, 2018 | December 31, 2023 | KIRKPATRICK, LYNN | reporter.nih.gov |
| Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,306,927 | September 15, 2018 | August 31, 2023 | KUO, LAWRENCE C | reporter.nih.gov |
| Antibody-based therapy for fentanyl-related opioid use disorder | NIH | National Institute on Drug Abuse | 2023 | $4,202,550 | September 30, 2023 | August 31, 2025 | DESAI, RAJEEV INDRAJIT | reporter.nih.gov |
| Development of novel therapeutics for opioid dependence | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,944,970 | September 30, 2018 | August 31, 2024 | KENNY, PAUL J. | reporter.nih.gov |
| Development and Implementation of a Culturally Centered Opioid Prevention Intervention for American Indian/Alaska Native Young Adults in California | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,791,983 | September 30, 2019 | August 31, 2025 | D'AMICO, ELIZABETH J. | reporter.nih.gov |
| Community Randomized Trial in the Cherokee Nation: CONNECT and CMCA for Preventing Drug Misuse among Older Adolescents | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,708,886 | September 30, 2019 | August 31, 2025 | KOMRO, KELLI ANN | reporter.nih.gov |
| Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components | NIH | National Institute on Drug Abuse | 2023 | $3,569,552 | September 15, 2018 | March 31, 2028 | COMER, SANDRA D | reporter.nih.gov |
| Prescription Opioid Misuse: A Pharmacist-Led Intervention at Point of Service Efficacy Trial | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,513,979 | March 15, 2021 | January 31, 2027 | COCHRAN, GERALD T. | reporter.nih.gov |
| Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD | NIH | National Institute on Drug Abuse | 2022 | $3,406,895 | September 30, 2019 | September 29, 2025 | SINHA, RAJITA | reporter.nih.gov |
| Genetics of oxycodone intake in a hybrid rat diversity panel. | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,392,750 | April 15, 2021 | January 31, 2027 | SHARP, BURT M | reporter.nih.gov |
| Perioperative Precision Medicine: Translating Science to Clinical Practice to Improve Safety and Efficacy of Opioids in Neonates, Children and Nursing Mothers | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $3,295,714 | August 3, 2022 | April 30, 2027 | SADHASIVAM, SENTHILKUMAR | reporter.nih.gov |
| Functional and Genomic Signatures of Escalated Fentanyl Use | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,237,608 | March 15, 2021 | December 31, 2026 | TURNER, JILL R. | reporter.nih.gov |
| Aging, Polypharmacy and Neurotoxicity in Adults Living with HIV | NIH | National Institute on Aging | 2021 to 2024 | $3,183,836 | May 1, 2020 | February 28, 2026 | MA, QING | reporter.nih.gov |
| Peripherally-restricted non-addictive cannabinoids for cancer pain treatment | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $3,174,343 | August 1, 2023 | July 31, 2025 | SPIGELMAN, IGOR | reporter.nih.gov |
| HEAL - ASSESSMENT OF POTENTIAL SUBSTANCE ABUSE TREATMENT MEDICATIONS IN NONHUMAN PRIMATE MODELS. NIDA REF. NO. N01DA-19-8946; POP: 12/16/2018-12/15/2022. | NIH | National Institute on Drug Abuse | 2022 to 2023 | $3,093,836 | December 16, 2018 | December 15, 2023 | BERGMAN, JACK | reporter.nih.gov |
| Opioid and SUD Data Enclave (O-SUDDEn): Bringing real-time data to the opioid crisis | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,921,106 | September 30, 2022 | August 31, 2027 | FERNANDEZ, SOLEDAD A | reporter.nih.gov |
| Effects of Sleep Disruption on Subjective Responses to Opioid Administration in Patients with Chronic Pain | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,894,566 | May 1, 2019 | February 28, 2026 | SMITH, MICHAEL T | reporter.nih.gov |
| Deterrents for prescription opioid abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,853,877 | September 15, 2015 | May 31, 2027 | FREEMAN, KEVIN B. | reporter.nih.gov |
| Opioid and cannabinoid interactions in pain and reward | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,852,096 | September 30, 2020 | June 30, 2026 | NEUBERT, JOHN K | reporter.nih.gov |
| The Role of the Dopamine Transporter in Psychostimulant Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,835,033 | July 1, 2014 | November 30, 2026 | GALLI, AURELIO | reporter.nih.gov |
| Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,790,999 | May 1, 2021 | February 28, 2027 | BRUEHL, STEPHEN | reporter.nih.gov |
| Single-cell resolution analysis of chromatin accessibility and gene expression changes in a model of drug addiction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,772,633 | May 1, 2020 | February 28, 2026 | TELESE, FRANCESCA | reporter.nih.gov |
| Benzodiazepine mediated mechanisms of transcriptional semi-quiescence in discrete myeloid populations | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,741,871 | September 15, 2022 | June 30, 2027 | GASKILL, PETER JESSE | reporter.nih.gov |
| Decoding the grammar of transcriptional enhancers regulating different stages of opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,717,399 | September 30, 2020 | July 31, 2026 | TELESE, FRANCESCA | reporter.nih.gov |
| Strategies to define and mitigate the placental and fetal alterations caused by maternal oxycodone exposure | NIH | National Institute on Drug Abuse | 2023 | $2,655,006 | August 1, 2023 | July 31, 2026 | HARRIS, LYNDA KATHERINE | reporter.nih.gov |
| Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorderand Tolerance in the Treatment of Pain | NIH | National Institute on Drug Abuse | 2023 | $2,579,875 | September 1, 2023 | August 31, 2025 | MEYN, MALCOLM A | reporter.nih.gov |
| Unintended Prolonged Opioid Use | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $2,552,781 | March 15, 2019 | August 31, 2024 | HOOTEN, W. MICHAEL | reporter.nih.gov |
| Research Examining Factors Associated with the Opioid Crisis among Underserved African Americans (REFOCUS) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,545,081 | September 30, 2020 | July 31, 2025 | STEVENS-WATKINS, DANELLE J | reporter.nih.gov |
| Development of an oral analgesic with reduced liabilities | NIH | National Institute on Drug Abuse | 2022 to 2023 | $2,500,000 | April 15, 2022 | March 31, 2025 | GEHLERT, DONALD R | reporter.nih.gov |
| Multiomic profiling of cell types mediating opioid use disorder in rats | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,491,424 | August 15, 2022 | April 30, 2027 | TELESE, FRANCESCA | reporter.nih.gov |
| Integrative Modeling of HIV-Associated Neurocognitive Disorder in Human Brain Organoids | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,456,170 | August 1, 2020 | May 31, 2025 | NOVITCH, BENNETT G | reporter.nih.gov |
| Ventral pallidal transcriptional adaptations underlying punishment-resistant opioid intake | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,423,094 | September 30, 2023 | May 31, 2028 | CREED, MEAGHAN C | reporter.nih.gov |
| Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool. | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,380,820 | September 26, 2019 | July 31, 2025 | MAIDMENT, NIGEL T | reporter.nih.gov |
| Integrative single-cell spatial transcriptomic, anatomical, and functional profiling of brain-wide ensembles engaged by opioid relapse | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,359,515 | September 30, 2023 | June 30, 2028 | GOLDEN, SAM | reporter.nih.gov |
| The impact of early life opioid exposure on the molecular and functional trajectories of septal cell types | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,334,521 | September 30, 2023 | June 30, 2028 | HARWELL, COREY C | reporter.nih.gov |
| Examining the synergistic effects of cannabis and prescription opioid policies on chronic pain, opioid prescribing, and opioid overdose | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,319,128 | January 1, 2019 | November 30, 2025 | CERDA, MAGDALENA | reporter.nih.gov |
| Non-opiate topical formulations for treating pain associated with molar extractions | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $2,257,823 | September 18, 2018 | February 29, 2024 | PARR, ALAN | reporter.nih.gov |
| Neuroimaging response inhibition and salience attribution changes during mindfulness-based treatment of human heroin addiction | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $2,253,926 | August 15, 2019 | June 30, 2024 | GOLDSTEIN, RITA Z | reporter.nih.gov |
| Impact of prescription stimulants on the drug overdose epidemic | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,253,245 | May 1, 2023 | March 31, 2028 | DE NADAI, ALESSANDRO STEVENS | reporter.nih.gov |
| Increased CNS Opioid Exposure by an Acetaminophen-Induced Blood-Brain Barrier Mechanism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,240,104 | July 1, 2020 | May 31, 2026 | DAVIS, THOMAS PAUL | reporter.nih.gov |
| Endocannabinoid Targeting for Opioid Induced Respiratory Depression | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,190,554 | July 1, 2022 | June 30, 2027 | MILNES, TALLY MARIE | reporter.nih.gov |
| Sex-specific mechanisms underlying the effects of pain on opioid seeking | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,163,671 | September 15, 2022 | June 30, 2027 | MORON-CONCEPCION, JOSE A | reporter.nih.gov |
| Enhancing Infrastructure for Clinical and Translational Research to Address the Opioid Epidemic | NIH | National Center for Advancing Translational Sciences | 2021 to 2023 | $2,152,222 | August 6, 2019 | June 30, 2024 | LENERT, LESLIE A. | reporter.nih.gov |
| Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,110,556 | September 30, 2019 | August 31, 2025 | BRIONES, MARISA | reporter.nih.gov |
| Benzodiazepine Choice and Polydrug Use | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,074,200 | April 1, 2022 | January 31, 2027 | HUSKINSON, SALLY L | reporter.nih.gov |
| A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypes | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,072,058 | September 1, 2020 | June 30, 2024 | ZACHARIOU, VENETIA | reporter.nih.gov |
| A Novel Opioid-Free Targeted Pain Control Method for Acute Post-Operative Localized Pain Related to Oral Surgical Procedures | NIH | National Institute of Dental & Craniofacial Research | 2023 | $2,050,357 | September 19, 2019 | September 18, 2025 | JADIA, RAHUL | reporter.nih.gov |
| Influence of Orexin Antagonism on Opioid and Methamphetamine Demand | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,047,388 | April 15, 2023 | December 1, 2025 | STRICKLAND, JUSTIN CHARLES | reporter.nih.gov |
| Empowering dentists to reduce opioid prescriptions to young people | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $2,035,344 | January 1, 2023 | December 31, 2028 | OYLER, DOUGLAS | reporter.nih.gov |
| Oxycodone, Neonatal Opioid Withdrawal Syndrome, and Adult Abuse Liability | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,030,768 | August 1, 2020 | May 31, 2026 | BYRNES, ELIZABETH M | reporter.nih.gov |
| Evaluating Policy Interventions to Decrease Excessive and Risky Perioperative Opioid Prescribing | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,027,866 | September 1, 2022 | October 31, 2024 | WALJEE, JENNIFER FILIP | reporter.nih.gov |
| Identifying Genetic Variants Associated with Opioid Overdose Mortality | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,020,602 | July 1, 2018 | April 30, 2024 | NELSON, ELLIOT C | reporter.nih.gov |
| Integrated Treatment for Veterans with Co-Occurring Chronic Pain and Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,994,995 | September 30, 2019 | August 31, 2025 | WITKIEWITZ, KATIE A | reporter.nih.gov |
| Developing and Evaluating a Machine-Learning Opioid Prediction & Risk-Stratification E-Platform (DEMONSTRATE) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,991,133 | July 1, 2021 | November 1, 2023 | LO-CIGANIC, WEI-HSUAN | reporter.nih.gov |
| Determinants of Drug Preference in Humans | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,905,360 | January 1, 1981 | January 31, 2026 | DE WIT, HARRIET | reporter.nih.gov |
| Abuse-deterrence and prevention of respiratory depression by an oral opioid analgesic and doxapram combination | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,904,562 | September 1, 2022 | February 28, 2026 | RIX, PETER JEFFREY | reporter.nih.gov |
| Tolerance and Physical Dependence after Chronic Benzodiazepine Treatment | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,872,481 | June 1, 2002 | February 29, 2028 | ROWLETT, JAMES K | reporter.nih.gov |
| Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policies | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,868,751 | September 30, 2018 | August 31, 2025 | GREENWALD, MARK K | reporter.nih.gov |
| Dissecting ventral pallidal plasticity in punishment-resistant opioid self-administration | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,862,776 | June 15, 2023 | March 31, 2028 | CREED, MEAGHAN C | reporter.nih.gov |
| The Symptom-Associated Pathway to Substance Use and Misuse during Adolescence | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,852,500 | September 1, 2021 | July 31, 2027 | VOEPEL-LEWIS, TERRI DIANE | reporter.nih.gov |
| Nonaddictive opioid prodrug nanomedicine for musculoskeletal pain | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,851,532 | September 7, 2022 | July 31, 2027 | WANG, DONG | reporter.nih.gov |
| Sleep deficiency and opioid use/misuse in adolescents following surgery | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,850,649 | September 10, 2023 | August 31, 2028 | GROENEWALD, CORNELIUS BOTHA | reporter.nih.gov |
| Endocannabinoid Metabolism in Acute Pain | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,844,228 | April 15, 2020 | February 28, 2026 | KACZOCHA, MARTIN | reporter.nih.gov |
| Microglia and Epigenetic Regulation in Opioid Addiction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,842,000 | July 1, 2020 | May 31, 2025 | TUESTA, LUIS MIGUEL | reporter.nih.gov |
| Identification of genes and genetic networks contributing to opioid use disorder traits in the Hybrid Rat Diversity Panel | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,834,833 | August 1, 2020 | May 31, 2026 | EHRINGER, MARISSA A | reporter.nih.gov |
| Validation of the TAPS-Electronic Spanish Platform (TAPS-ESP): A Technology to Improve Access to Substance Use Screening and Reduce Behavioral Health Disparities in Hispanic Primary Care Patients | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,833,979 | September 19, 2018 | May 31, 2025 | CARSWELL, STEVEN BERNARD | reporter.nih.gov |
| An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,828,326 | June 1, 2020 | August 31, 2024 | YORK, CHRISTINA | reporter.nih.gov |
| Title: Pharmacokinetic, pharmacodynamic , and toxicological interactions among Opioids and Cabotegravir | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,790,275 | September 1, 2022 | July 31, 2027 | EL-HAGE, NAZIRA | reporter.nih.gov |
| Mining Social Media Big Data for Toxicovigilance: Studying Substance Use via Natural Language Processing and Machine Learning Methods | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,773,166 | September 30, 2022 | July 31, 2027 | SARKER, ABEED H | reporter.nih.gov |
| Bench-top Reader and Aptamer-based Assay for Rapid, High-sensitivity Drug/Opiate Detection | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,763,772 | September 15, 2023 | July 31, 2027 | JACKSON, GEORGE W | reporter.nih.gov |
| Buprenorphine analogs for the treatment of opioid abuse | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,731,161 | March 1, 2021 | January 31, 2027 | KO, MEI-CHUAN | reporter.nih.gov |
| The Genetic Basis of Opioid Dependence Vulnerablility in a Rodent Model | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,704,402 | September 30, 2018 | July 31, 2024 | KALIVAS, PETER W | reporter.nih.gov |
| Preventing prescription opioid misuse among employees working in high risk industries. | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,626,195 | September 30, 2019 | April 30, 2026 | HEBARD, STEPHEN | reporter.nih.gov |
| The Role of Microbiome Composition in Amphetamine Abuse | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,621,263 | August 15, 2023 | May 31, 2028 | GALLI, AURELIO | reporter.nih.gov |
| Anxiolytic Effects and Abuse of BZ Receptor Ligands | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,607,424 | June 15, 1998 | April 30, 2026 | ROWLETT, JAMES K | reporter.nih.gov |
| CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and Dependence | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,551,552 | April 15, 2019 | February 28, 2026 | HOHMANN, ANDREA GRACE | reporter.nih.gov |
| Opioid Treatment of Pain in People with Cancer: Intended and unintended consequences of state policies addressing opioid prescribing | NIH | National Cancer Institute | 2022 to 2025 | $1,523,785 | September 20, 2022 | August 31, 2026 | BAO, YUHUA | reporter.nih.gov |
| Fentanyl use during pregnancy: impact on dam, placenta, and offspring development. | NIH | National Institute on Drug Abuse | 2023 | $1,509,492 | August 1, 2023 | July 31, 2026 | RÜEDI-BETTSCHEN, DANIELA | reporter.nih.gov |
| Reduced complexity mapping of oxycodone self-administration and stress responsiveness in rats | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,379,892 | May 1, 2020 | February 28, 2026 | CHEN, HAO | reporter.nih.gov |
| Mechanisms of Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,374,754 | July 16, 2024 | April 30, 2029 | THEKEN, KATHERINE NICOLE | reporter.nih.gov |
| Using opioid industry documents to understand marketing of addictive medications | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,361,397 | September 15, 2024 | May 31, 2029 | APOLLONIO, DOROTHY ELINOR | reporter.nih.gov |
| The Opioid Crisis: The Effects and Unintended Consequences of State Policies on Opioid Analgesic Prescribing | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,288,703 | March 15, 2019 | December 31, 2023 | STEIN, BRADLEY D | reporter.nih.gov |
| Risk for opioid abuse and misuse in adolescence | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,287,806 | March 15, 2018 | December 31, 2024 | WILSON, ANNA CAMILLE | reporter.nih.gov |
| Reducing morbidity and mortality from overdose, HIV, and hepatitis C in opioid-using persons | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,262,543 | September 1, 2018 | June 30, 2024 | BRAITHWAITE, RONALD SCOTT | reporter.nih.gov |
| Single cell multi-omics of iPSC-derived brain organoids from patients with opioid use disorder: synthetic opioids as molecular probes | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,252,839 | July 15, 2023 | May 31, 2028 | HO, MING-FEN | reporter.nih.gov |
| Delineating the role of serotonin 5-HT2 receptors in opioid use disorders: Development of novel 5-HT2 modulators with translational studies in rodents and primates | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,219,349 | August 1, 2018 | May 31, 2026 | BOOTH, RAYMOND G. | reporter.nih.gov |
| Developing and Evaluating a Machine-Learning Opioid Prediction & Risk-Stratification E-Platform (DEMONSTRATE) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,212,241 | July 1, 2021 | April 30, 2027 | LO-CIGANIC, WEI-HSUAN JENNY | reporter.nih.gov |
| Trajectories of Prescription Nonmedical Drug Misuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,194,681 | April 1, 2011 | March 31, 2028 | MCCABE, SEAN ESTEBAN | reporter.nih.gov |
| Substance Use in Reservists: Social and Environmental Influences | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,192,691 | June 1, 2013 | July 31, 2025 | HOMISH, GREGORY G. | reporter.nih.gov |
| Molecular and Cellular Profiling of the Habenulointerpeduncular Circuit in Opioid Tolerance and Withdrawal | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,188,822 | September 15, 2024 | May 31, 2029 | ABLES, JESSICA | reporter.nih.gov |
| Implementation, Outcomes, and Cost of a Novel Medicaid Policy to Reduce Opioids for Back Pain | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,181,590 | August 15, 2018 | May 31, 2024 | CHOO, ESTHER K | reporter.nih.gov |
| Incubation of oxycodone craving and nucleus accumbens plasticity | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,166,080 | September 30, 2024 | May 31, 2029 | WOLF, MARINA ELIZABETH | reporter.nih.gov |
| DAT-Regulation of Nucleus Accumbens Microcircuitry by Oxycodone Exposure and Withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,155,000 | September 1, 2019 | July 31, 2025 | ROTHWELL, PATRICK | reporter.nih.gov |
| Effects of State Laws to Reduce Opioid Diversion on Transitions to Injection Drug Use and HIV/HCV Transmission | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,137,366 | April 1, 2018 | December 31, 2023 | DICKSON-GOMEZ, JULIA B | reporter.nih.gov |
| Licit and Illicit Opioids: Comparative Studies in Humans | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,134,119 | July 10, 2004 | July 31, 2025 | WALSH, SHARON L. | reporter.nih.gov |
| MyTPill: A Novel Strategy to Monitor Antiretroviral Adherence among HIV+ Prescription Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,133,812 | June 1, 2019 | April 30, 2025 | BOYER, EDWARD W | reporter.nih.gov |
| Harnessing big data to arrest the HIV/HCV/opioid syndemic in the rural and urban South | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,115,625 | June 1, 2023 | March 31, 2028 | REBEIRO, PETER F | reporter.nih.gov |
| Opioid-induced dysregulation of cortico-striatal circuits | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,083,671 | July 1, 2023 | April 30, 2028 | HEARING, MATTHEW CARL | reporter.nih.gov |
| Improving pain management and opioid safety through a systemwide, data driven evaluation of the CDC opioid prescribing guideline best practices and the use of Clinical Decision Support | NIH | National Institute on Drug Abuse | 2022 | $1,072,844 | September 30, 2022 | September 29, 2024 | HOPPE, JASON | reporter.nih.gov |
| Effectiveness, toxicity and safety of opioid and benzodiazepine substitutes | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,066,500 | September 15, 2016 | April 30, 2026 | KUO, YONG-FANG | reporter.nih.gov |
| Psychological Risk Factors for Persistent Opioid Use and Prevention of Chronic Opioid Use and Misuse After Surgery: Postoperative Motivational Interviewing and Guided Opioid Weaning | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,041,294 | September 1, 2018 | June 30, 2024 | HAH, JENNIFER | reporter.nih.gov |
| Using a Novel Comprehensive Linked Dataset to Determine Early Predictors of Opioid Overdose | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,016,161 | September 30, 2018 | August 31, 2024 | WEINER, SCOTT GORDON | reporter.nih.gov |
| Serotonin receptors that potentiate addiction-related behavioral and molecular effects induced by methylphenidate plus SSRI exposure | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,013,596 | April 1, 2019 | January 31, 2024 | STEINER, HEINZ | reporter.nih.gov |
| Optopharmacology and Sensors for Dissecting Opioid Action In Vivo | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,005,835 | September 30, 2020 | August 31, 2025 | BRUCHAS, MICHAEL R. | reporter.nih.gov |
| Structure and Function of GABA-A Receptors | NIH | National Institute on Drug Abuse | 2021 to 2022 | $995,664 | February 1, 2019 | December 31, 2023 | HIBBS, RYAN E | reporter.nih.gov |
| Opioid-Sparing pain management for Chronic Low Back Pain patients using TMC-CP01 - A VANISH (Virtual Autonomic Neuromodulation Induced Systemic Healing) based program | NIH | National Institute on Drug Abuse | 2022 | $989,571 | September 30, 2019 | December 31, 2024 | TIEN, CELINE | reporter.nih.gov |
| Optimization of novel thioesters as a therapeutic strategy for combating opioid overdoses and abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $956,514 | September 1, 2020 | July 31, 2023 | LEWIS, STEPHEN JOHN | reporter.nih.gov |
| Community-based, client-centered prevention homes to address the rural opioid epidemic | NIH | National Institute on Drug Abuse | 2021 to 2022 | $941,278 | August 15, 2017 | July 31, 2023 | WESTERGAARD, RYAN PATRICK | reporter.nih.gov |
| Longitudinal Changes in Prescription Drug Misuse and Polysubstance Use in Adolescents and Young Adults | NIH | National Institute on Drug Abuse | 2023 to 2025 | $939,705 | June 1, 2017 | July 31, 2027 | SCHEPIS, TY STEPHEN | reporter.nih.gov |
| Molecular and Dynamic Insights into the Function of GPCRs Involved in Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $932,192 | August 1, 2018 | May 31, 2025 | FILIZOLA, MARTA | reporter.nih.gov |
| Thalamic Circuits Underlying Opioid Seeking | NIH | National Institute on Drug Abuse | 2021 to 2022 | $913,114 | September 30, 2018 | June 30, 2024 | CHEN, XIAOKE | reporter.nih.gov |
| Chemical biology tools for illuminating cannabinoid signaling pathways in opioid use disorder. | NIH | National Institute on Drug Abuse | 2024 to 2025 | $842,400 | August 15, 2024 | May 31, 2029 | FRANK, JAMES ALLEN | reporter.nih.gov |
| Research and Mentoring in Innovative Patient Oriented Pain and Opioid Science | NIH | National Institute on Drug Abuse | 2021 to 2025 | $837,632 | May 1, 2021 | April 30, 2026 | DARNALL, BETH DENISE | reporter.nih.gov |
| Discovery of GPR52 ligand probes for cocaine use disorder | NIH | National Institute on Drug Abuse | 2025 | $795,090 | September 1, 2025 | May 31, 2030 | ALLEN, JOHN A | reporter.nih.gov |
| RELIEPH for Interstitial Cystitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $769,386 | July 1, 2018 | March 31, 2024 | XU, YAN | reporter.nih.gov |
| Leveraging Integrative Modeling and AI-Based Tools to Develop Safer Opioids | NIH | National Institute on Drug Abuse | 2025 | $767,506 | July 1, 2025 | March 31, 2030 | FILIZOLA, MARTA | reporter.nih.gov |
| Optopharmacology and Sensors for Dissecting Opioid Action In Vivo | NIH | National Institute on Drug Abuse | 2021 to 2022 | $761,628 | September 30, 2020 | August 31, 2023 | BRUCHAS, MICHAEL R. | reporter.nih.gov |
| The role of central amylin receptor in opioid-mediated behaviors | NIH | National Institute on Drug Abuse | 2025 | $759,339 | July 1, 2025 | March 31, 2030 | SCHMIDT, HEATH D | reporter.nih.gov |
| Improving the Safety of Treatment for Hospitalized Patients with Alcohol Withdrawal Syndrome | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $752,112 | September 20, 2022 | August 31, 2027 | STEEL, TESSA LYNNE | reporter.nih.gov |
| The Role of HIV Proteins in Psychostimulant Abuse | NIH | National Institute on Drug Abuse | 2025 | $751,112 | May 1, 2025 | March 31, 2030 | GALLI, AURELIO | reporter.nih.gov |
| Cucurbituril Type Receptors as Sequestration Agents for Drugs of Abuse | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $747,910 | April 15, 2019 | January 31, 2024 | ISAACS, LYLE D | reporter.nih.gov |
| Elucidating behavior and neural circuits underlying opioid addiction and dependence | NIH | National Institute on Drug Abuse | 2023 to 2025 | $747,000 | September 1, 2019 | January 31, 2027 | NGUYEN, JACQUES DUCHUY | reporter.nih.gov |
| Discovery of novel pharmacotherapeutic targets for opioid addiction | NIH | National Institute on Drug Abuse | 2022 to 2024 | $746,999 | August 1, 2020 | March 31, 2026 | SMITH, ALEXANDER WANLESS | reporter.nih.gov |
| Prescription Stimulant Supply Shocks: Assessing the Impacts on Health Outcomes and Disparities | NIH | National Institute of Mental Health | 2025 | $729,367 | December 18, 2024 | November 30, 2028 | SMART, ROSANNA | reporter.nih.gov |
| Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination | NIH | National Institute on Drug Abuse | 2022 to 2025 | $723,453 | January 1, 2022 | December 31, 2026 | BERRY, MEREDITH | reporter.nih.gov |
| Explicating Vulnerability and Resilience in Opioid Self-Administration in Middle Aged Rats | NIH | National Institute on Drug Abuse | 2024 to 2025 | $715,500 | September 15, 2024 | June 30, 2029 | TAFFE, MICHAEL A. | reporter.nih.gov |
| Multivariate genome-wide association analysis of opioid-related traits in half a million diverse individuals | NIH | National Institute on Drug Abuse | 2025 | $715,238 | January 15, 2025 | November 30, 2029 | SANCHEZ ROIGE, SANDRA | reporter.nih.gov |
| Affective and Inflammatory Reactivity to Pain in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $714,008 | September 30, 2019 | July 31, 2025 | MCHUGH, REBECCA KATHRYN | reporter.nih.gov |
| Co-Use of Opioid Medications and Alcohol Prevention Study (COAPS) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2024 | $708,250 | May 26, 2022 | April 30, 2026 | COCHRAN, GERALD T. | reporter.nih.gov |
| Screening and Brief Intervention for Prescription Stimulant Misuse and Diversion: Refining and Piloting a Curriculum for College Health Providers | NIH | National Institute on Drug Abuse | 2023 to 2025 | $672,656 | July 15, 2023 | May 31, 2027 | BAVARIAN, NILOOFAR | reporter.nih.gov |
| Pain Medication Prescriptions and Misuse Following Treatment for Alcohol Use Disorders | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $652,259 | August 1, 2020 | December 31, 2024 | LEONARD, KENNETH E | reporter.nih.gov |
| Benzodiazepine-related harms in young people: Informing policy, interventions, and prescribing | NIH | National Institute on Drug Abuse | 2023 to 2025 | $647,316 | March 15, 2021 | February 28, 2027 | BUSHNELL, GRETA | reporter.nih.gov |
| Using Default Opioid Prescription Settings to Limit Excessive Opioid Prescribing to Adolescents and Young Adults | NIH | National Institute on Drug Abuse | 2021 to 2023 | $589,680 | May 1, 2019 | April 30, 2024 | CHUA, KAO-PING | reporter.nih.gov |
| Modeling weekly and daily processes of a high-risk feedback cycle of alcohol, cannabis, and nonmedical use of prescription stimulants in college students: Impacts on use, academics, and sleep | NIH | National Institute on Drug Abuse | 2025 | $589,440 | May 15, 2025 | February 28, 2030 | FAIRLIE, ANNE MARIE | reporter.nih.gov |
| A Tailored Behavioral Intervention To Increase Engagement in Opioid Tapering in Primary Care Settings | NIH | National Institute on Drug Abuse | 2021 to 2023 | $582,473 | July 1, 2019 | December 31, 2024 | LAGISETTY, POOJA | reporter.nih.gov |
| Empowering dentists to reduce opioid prescriptions to young people | NIH | National Institute of Dental & Craniofacial Research | 2023 | $580,179 | January 1, 2023 | December 31, 2023 | OYLER, DOUGLAS | reporter.nih.gov |
| Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD adherence to adolescents with OUD | NIH | National Institute on Drug Abuse | 2024 | $576,675 | September 30, 2024 | August 31, 2027 | WENZEL, KEVIN R. | reporter.nih.gov |
| Variable brain oxycodone metabolism alters drug effect | NIH | National Institute on Drug Abuse | 2021 to 2022 | $576,531 | September 30, 2018 | July 31, 2024 | TYNDALE, RACHEL FYNVOLA | reporter.nih.gov |
| Polydrug Abuse: Opioid-Alcohol Combinations | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $571,673 | September 23, 2025 | July 31, 2030 | PLATT, DONNA M | reporter.nih.gov |
| PrEP and substance use among sexual minority young adults | NIH | National Institute on Drug Abuse | 2021 to 2023 | $571,335 | April 1, 2019 | March 31, 2025 | WATSON, RYAN J | reporter.nih.gov |
| Nicotinic and Insular Cortical Mechanisms Contributing to Opiate Misuse | NIH | National Institute on Drug Abuse | 2021 to 2024 | $547,022 | May 1, 2024 | July 31, 2025 | LONEY, GREGORY CARL | reporter.nih.gov |
| Low-dose buccal buprenorphine: Relative abuse potential and postoperative analgesic acceptability | NIH | National Institute on Drug Abuse | 2023 to 2025 | $526,926 | March 15, 2023 | February 29, 2028 | LARACH, DANIEL | reporter.nih.gov |
| Reducing Unused Prescribed Opioids After Cesarean Birth | NIH | National Institute on Drug Abuse | 2021 to 2023 | $508,978 | August 1, 2019 | July 31, 2024 | OSMUNDSON, SARAH SCHEIDERICH | reporter.nih.gov |
| Development and Pilot Randomized Control Trial of a Text Message Intervention to Facilitate Secure Storage and Disposal of Prescription Opioids to Prevent Diversion and Misuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $503,877 | August 1, 2021 | July 31, 2023 | EGAN, KATHLEEN LOUISE | reporter.nih.gov |
| Safety Assessment of Perioperative Pain Medications for Children (SAPPhire) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $489,697 | August 20, 2021 | July 31, 2024 | RAVAL, MEHUL V. | reporter.nih.gov |
| EpiCenter - EPIdemiology of opioid prescribing in community health CENTERs | NIH | National Institute on Drug Abuse | 2022 | $483,221 | August 1, 2018 | April 30, 2023 | HARTUNG, DANIEL M | reporter.nih.gov |
| Changes to which Drugs and Drug Combinations are Prescribed in Response to Opioid Supply-side Policies | NIH | National Institute on Drug Abuse | 2021 to 2022 | $478,166 | September 30, 2021 | August 31, 2025 | PEET, EVAN DAVID | reporter.nih.gov |
| Single Session Pain Catastrophizing Class: Efficacy & Mechanisms for Reducing Opioid Use Among Chronic Pain Patients | NIH | National Institute on Drug Abuse | 2021 to 2023 | $477,657 | May 15, 2019 | November 30, 2024 | ZIADNI, MAISA | reporter.nih.gov |
| Impact of cannabis legalization on prescription drug use and health outcomes in Connecticut | NIH | National Institute on Drug Abuse | 2023 to 2024 | $475,440 | April 1, 2023 | March 31, 2025 | RADHAKRISHNAN, RAJIV | reporter.nih.gov |
| Understanding and Addressing Opioid and Benzodiazepine Co-prescribing among Older Adults with Cancer | NIH | National Institute on Aging | 2022 to 2023 | $466,440 | February 15, 2022 | November 30, 2024 | CHECK, DEVON | reporter.nih.gov |
| Role of lateral hypothalamus projections in opioid withdrawal-induced sleep deficits | NIH | National Institute on Drug Abuse | 2022 to 2023 | $466,310 | July 1, 2022 | June 30, 2025 | CARLEZON, WILLIAM A. | reporter.nih.gov |
| Evaluating Policy Interventions to Decrease Excessive and Risky Perioperative Opioid Prescribing | NIH | National Institute on Drug Abuse | 2025 | $465,336 | February 28, 2025 | April 30, 2027 | WALJEE, JENNIFER FILIP | reporter.nih.gov |
| Spinal Manipulative Therapy vs. Prescription Drug Therapy for Care of Aged Medicare Beneficiaries with Neck Pain | NIH | National Center for Complementary & Integrative Health | 2022 | $459,595 | August 1, 2018 | April 30, 2025 | WHEDON, JAMES M. | reporter.nih.gov |
| Effect of pain catastrophizing on prescription opioid craving | NIH | National Institute on Drug Abuse | 2021 to 2023 | $454,533 | July 1, 2019 | December 31, 2024 | YOU, DOKYOUNG SOPHIA | reporter.nih.gov |
| Long-term Opioid Therapy, Depression and Suicide Mortality Risk in Patients with Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2022 | $447,950 | September 15, 2022 | September 14, 2025 | OSAZUWA-PETERS, NOSAYABA | reporter.nih.gov |
| Resolving differences between clinical opioids at single neurons | NIH | National Institute on Drug Abuse | 2021 to 2022 | $444,125 | March 1, 2021 | February 29, 2024 | MARGOLIS, ELYSSA | reporter.nih.gov |
| Functional consequences of the interactions between tau protein and opioids | NIH | National Institute on Drug Abuse | 2024 to 2025 | $441,176 | September 15, 2024 | August 31, 2026 | ATWOOD, BRADY | reporter.nih.gov |
| Spillover Effects of Policies Targeting Opioid Abuse on Intimate Partner Violence | NIH | National Institute on Drug Abuse | 2024 to 2025 | $438,703 | June 1, 2024 | May 31, 2026 | DAVE, DHAVAL M. | reporter.nih.gov |
| Early cannabis use and later opioid use disorder - the role of adverse childhood experiences, genetic liability and comorbid stimulant use | NIH | National Institute on Drug Abuse | 2024 to 2025 | $427,625 | August 1, 2024 | July 31, 2027 | AGRAWAL, ARPANA | reporter.nih.gov |
| Consequences of fentanyl self-administration during pregnancy | NIH | National Institute on Drug Abuse | 2021 to 2022 | $426,250 | April 1, 2021 | March 31, 2024 | RÜEDI-BETTSCHEN, DANIELA | reporter.nih.gov |
| Macrocyclic Arenes as Sequestrants for Drugs of Abuse | NIH | National Institute on Drug Abuse | 2024 to 2025 | $425,976 | June 15, 2024 | May 31, 2027 | ISAACS, LYLE D | reporter.nih.gov |
| The potential of oxytocin to reduce opioid abuse liability and pain among older adults | NIH | National Institute on Drug Abuse | 2023 to 2024 | $419,375 | May 1, 2023 | April 30, 2026 | BERRY, MEREDITH | reporter.nih.gov |
| Transcriptional silencing of HIV by LTR targeting RNAi | NIH | National Institute on Drug Abuse | 2025 | $418,625 | July 15, 2025 | June 30, 2027 | KLASE, ZACHARY ALAN | reporter.nih.gov |
| Providers and Older Pain Patients with Prescription Opioid Dependence: A Qualitative Study to Understand Barriers to Opioid Taper, Cessation, and Transition to Buprenorphine. | NIH | National Institute on Aging | 2023 | $416,625 | September 19, 2023 | September 18, 2025 | GRUCZA, RICHARD A | reporter.nih.gov |
| Counterfeit Pharmaceuticals: Increased Risks in the Era of Novel Synthetic Opioids and Other Designer Drugs | NIH | National Institute on Drug Abuse | 2022 to 2023 | $415,340 | April 1, 2022 | March 31, 2025 | DANIULAITYTE, RAMINTA | reporter.nih.gov |
| An Examination of Concomitant Non-Medical Use of Gabapentin and Opioids. | NIH | National Institute on Drug Abuse | 2022 to 2023 | $412,363 | September 30, 2022 | August 31, 2025 | BUTTRAM, MANCE E. | reporter.nih.gov |
| Brain Development after Early-Life Antipsychotic Treatment | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $411,000 | June 1, 2023 | April 30, 2027 | BARDGETT, MARK EDWARD | reporter.nih.gov |
| March5 and Associated Mitochondrial Dynamics in Incubation of Oxycodone Craving | NIH | National Institute on Drug Abuse | 2023 to 2024 | $410,136 | May 15, 2023 | April 30, 2026 | LI, XUAN ANNA | reporter.nih.gov |
| Subcellular Proteomics in Orbitostriatal Circuits in Incubation of Oxycodone Craving | NIH | National Institute on Drug Abuse | 2024 | $403,542 | September 15, 2024 | August 31, 2026 | LI, XUAN ANNA | reporter.nih.gov |
| Short-term Outcome of Stimulant Use Disorder Treatment Trials | NIH | National Institute on Drug Abuse | 2024 | $403,206 | July 1, 2024 | June 30, 2026 | MOJTABAI, RAMIN | reporter.nih.gov |
| The use of DNA-encoded library (DEL) technology for the identification of therapeutic molecules to treat opioid use disorders (OUDs) | NIH | National Institute on Drug Abuse | 2024 | $399,884 | September 1, 2024 | August 31, 2025 | FLAJOLET, MARC | reporter.nih.gov |
| iPSC-derived human neurons and OUD medications development | NIH | National Institute on Drug Abuse | 2025 | $399,536 | March 15, 2025 | February 28, 2027 | GOMEZ-GALENO, JORGE E. | reporter.nih.gov |
| Collaborative Care Office-Based Opioid Treatment for Adolescents and Young Adults | NIH | National Institute on Drug Abuse | 2021 to 2022 | $398,423 | October 5, 2021 | December 31, 2023 | HADLAND, SCOTT EVAN | reporter.nih.gov |
| Behavior Change Components to Enhance Opioid Disposal After Surgery | NIH | National Institute on Drug Abuse | 2024 to 2025 | $397,440 | May 1, 2024 | April 30, 2028 | HUANG, LYEN CAMILLE | reporter.nih.gov |
| Benzodiazepine-related harms in young people: Informing policy, interventions, and prescribing | NIH | National Institute on Drug Abuse | 2021 to 2022 | $392,212 | March 15, 2021 | February 28, 2023 | BUSHNELL, GRETA | reporter.nih.gov |
| Multi-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatality | NIH | National Institute on Drug Abuse | 2021 to 2022 | $392,212 | July 1, 2020 | June 30, 2023 | SAMPLES, HILLARY | reporter.nih.gov |
| Multi-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatality | NIH | National Institute on Drug Abuse | 2023 to 2024 | $392,212 | July 1, 2020 | June 30, 2026 | SAMPLES, HILLARY | reporter.nih.gov |
| Opioid-induced dysregulation of lateral mesolimbic dopamine circuits and motivated behavior | NIH | National Institute on Drug Abuse | 2021 to 2022 | $381,587 | September 30, 2021 | August 31, 2023 | HEARING, MATTHEW CARL | reporter.nih.gov |
| Facilitating supervised self-management of stimulant medications among adolescents: improving adherence, reducing stigma, and supporting caregivers | NIH | National Institute on Drug Abuse | 2021 to 2022 | $379,072 | June 1, 2021 | May 31, 2022 | PERSE, ARTIN | reporter.nih.gov |
| SPOiLER: towards Safer Prescribing of Legal Opioids from the Emergency Room | NIH | National Institute on Drug Abuse | 2021 to 2022 | $370,793 | March 1, 2018 | August 31, 2023 | SOARES, WILLIAM EDWARD | reporter.nih.gov |
| Postpartum Neurobiological Sequelae of Prescription Opioid Use During Pregnancy | NIH | National Institute on Drug Abuse | 2024 to 2025 | $369,930 | March 1, 2024 | May 30, 2025 | LUJAN PEREZ, MIGUEL ANGEL | reporter.nih.gov |
| Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities. | NIH | National Institute on Drug Abuse | 2023 to 2024 | $368,300 | February 1, 2024 | September 30, 2024 | CARRY, EILEEN | reporter.nih.gov |
| Using machine learning to analyze integrated clinical and geo-contextual data to inform the design of a decision support system to reduce the risk of stimulant therapy | NIH | National Institute on Drug Abuse | 2024 to 2025 | $361,792 | July 15, 2024 | June 30, 2029 | TUAN, WEN-JAN | reporter.nih.gov |
| Augmenting the Efficacy of Benzodiazepine Taper with Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids | NIH | National Institute on Drug Abuse | 2022 to 2023 | $360,141 | September 15, 2022 | August 31, 2025 | WOLITZKY-TAYLOR, KATE BASIA | reporter.nih.gov |
| Quantifying health policy impacts on substance use and treatment among women with and at risk for HIV: a longitudinal multilevel analysis using the Women's Interagency HIV Study | NIH | National Institute on Drug Abuse | 2021 to 2022 | $349,741 | July 18, 2020 | June 30, 2024 | HALEY, DANIELLE FRANCES | reporter.nih.gov |
| Leveraging large-scale national data to understand, reduce, and prevent benzodiazepine-related harms among older adults | NIH | National Institute on Drug Abuse | 2022 | $348,477 | May 15, 2018 | February 29, 2024 | MAUST, DONOVAN T | reporter.nih.gov |
| Dementia and the opioid epidemic: The impact of the 2016 CDC guidelines on disparities in pain management | NIH | National Institute on Aging | 2024 | $338,000 | September 17, 2024 | August 31, 2026 | RODIN, REBECCA ANNE | reporter.nih.gov |
| Functional and molecular characterization of the central amygdala in the context of oxycodone withdrawal | NIH | National Institute on Drug Abuse | 2024 to 2025 | $331,822 | May 1, 2024 | April 30, 2027 | SLIVICKI, RICHARD | reporter.nih.gov |
| Harnessing Placebo Analgesia to Address the Opioid Epidemic | NIH | National Institute on Drug Abuse | 2022 to 2023 | $330,981 | April 1, 2019 | September 30, 2024 | BERNSTEIN, MICHAEL HARRISON | reporter.nih.gov |
| Nucleus accumbens fast-spiking interneurons regulate opioid reward and addiction | NIH | National Institute on Drug Abuse | 2022 to 2023 | $329,130 | March 1, 2022 | February 29, 2024 | LEFEVRE, EMILIA M | reporter.nih.gov |
| SafeMedWaste At-Home, Environmentally-Friendly Opioid Disposal Kit for Orthopedic Post-Operative Surgical Patients to Reduce Opioids Available for Diversion | NIH | National Institute on Drug Abuse | 2023 | $323,698 | September 1, 2023 | August 31, 2025 | STAS, JUSTIN | reporter.nih.gov |
| An oral therapeutic to treat intoxication by prescription and illicit stimulants | NIH | National Institute on Drug Abuse | 2022 | $319,946 | September 30, 2022 | March 31, 2023 | LI, XINHUA | reporter.nih.gov |
| Theory-based social media intervention for non-medical use of prescription opioids (NMUPO) in young adults | NIH | National Institute on Drug Abuse | 2024 to 2025 | $311,558 | May 1, 2024 | April 30, 2029 | TAM, CHEUK CHI | reporter.nih.gov |
| Feasibility of a dual English/Spanish mobile augmented reality pain assessment app to reduce postoperative prescription opioid use in Hispanic/Latino pediatric and adolescent cancer patients | NIH | National Institute on Drug Abuse | 2022 to 2023 | $310,996 | March 6, 2023 | September 30, 2023 | YORK, CHRISTINA | reporter.nih.gov |
| Meeting the cost and privacy demands for detecting Anabolic Androgenic Steroid doping in youth athletics with rationally designed nuclear receptor BioAssays | NIH | National Institute on Drug Abuse | 2025 | $306,872 | February 1, 2025 | December 31, 2026 | SCHAUFELE, FRED J | reporter.nih.gov |
| Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention | NIH | National Institute on Drug Abuse | 2021 to 2022 | $306,592 | July 15, 2020 | May 31, 2024 | HOLT, LAURA | reporter.nih.gov |
| A Hybrid Program to Prevent Substance Use Risk among Upper Elementary School Students Using a Positive Youth Development Approach | NIH | National Institute on Drug Abuse | 2024 | $305,046 | September 15, 2024 | August 31, 2025 | WILLIAMS, CHRISTOPHER | reporter.nih.gov |
| Extending duration of an injectable long-acting local anesthetic formulation using novel salts | NIH | National Institute on Drug Abuse | 2024 | $295,921 | September 1, 2024 | August 31, 2025 | DAVIS, BRETT | reporter.nih.gov |
| Feasibility of Electronic Screening to Identify Risk of Opioid Misuse and Overdose | NIH | National Institute on Drug Abuse | 2024 | $295,876 | September 15, 2024 | August 31, 2025 | FERRARESE, NICK | reporter.nih.gov |
| Technologies for OUD Prevention, Control and Supportive Care - Development of Patient/Caregiver mobile application and Provider Dashboard | NIH | National Institute on Drug Abuse | 2021 to 2022 | $276,150 | September 15, 2021 | August 31, 2022 | ELUMALAI, SATHYA | reporter.nih.gov |
| Developing a novel epigenetic regulator as a treatment for opioid use disorder | NIH | National Institute on Drug Abuse | 2024 | $275,253 | September 30, 2024 | September 29, 2025 | KIM, THOMAS | reporter.nih.gov |
| An mHealth Approach to Decreasing Opioid Abuse and Other Diseases of Despair in Rural Populations | NIH | National Institute on Drug Abuse | 2023 | $274,791 | September 15, 2023 | July 31, 2024 | DEITZ, DIANE K. | reporter.nih.gov |
| Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities | NIH | National Institute on Drug Abuse | 2022 to 2023 | $262,289 | April 1, 2022 | March 31, 2024 | MCLAURIN, KRISTEN ADDIE | reporter.nih.gov |
| Sedative-Hypnotic Use Patterns and Risk for Cognitive Decline and Alzheimer's Disease | NIH | National Institute on Aging | 2022 to 2023 | $255,420 | February 15, 2019 | January 31, 2025 | KAUFMANN, CHRISTOPHER NORFLEET | reporter.nih.gov |
| Elucidating behavior and neural circuits underlying opioid addiction and dependence | NIH | National Institute on Drug Abuse | 2022 | $234,963 | September 1, 2019 | August 31, 2022 | NGUYEN, JACQUES DUCHUY | reporter.nih.gov |
| Mechanism and Efficacy of a Novel Opioid Adjuvant | NIH | National Institute on Drug Abuse | 2024 | $220,668 | August 1, 2024 | August 31, 2025 | MEYN, MALCOLM A | reporter.nih.gov |
| Harnessing Placebo Analgesia to Address the Opioid Epidemic | NIH | National Institute on Drug Abuse | 2021 to 2022 | $211,519 | April 1, 2019 | July 31, 2022 | BERNSTEIN, MICHAEL HARRISON | reporter.nih.gov |
| Development and Pilot Randomized Control Trial of a Text Message Intervention to Facilitate Secure Storage and Disposal of Prescription Opioids to Prevent Diversion and Misuse | NIH | National Institute on Drug Abuse | 2023 | $195,173 | August 1, 2021 | May 31, 2026 | EGAN, KATHLEEN LOUISE | reporter.nih.gov |
| Cross-state validation of a novel prescription-based model to predict new long-term opioid use | NIH | National Institute on Drug Abuse | 2022 to 2023 | $173,286 | July 1, 2022 | June 30, 2025 | TSEREGOUNIS, IRAKLIS ERIK | reporter.nih.gov |
| Adolescent Oxycodone Exposure on Oxycodone Reinforcement and Reward Neurocircuitry in Adulthood | NIH | National Institute on Drug Abuse | 2021 to 2022 | $158,500 | July 15, 2021 | June 30, 2024 | HAUSER, SHEKETHA RENAY | reporter.nih.gov |
| Quantification and Characterization of Opioid Prescription, Overdose, and Fatalities in People with Cancer: A Massive Nationwide, Multi-Cohort Study | NIH | National Institute on Drug Abuse | 2021 to 2022 | $157,938 | April 1, 2021 | March 31, 2023 | MURPHY, JAMES D | reporter.nih.gov |
| Assessing Implementation of Pharmacy-Based Medication Disposal Programs: National Estimates, Neighborhood Inequities, and Determinants of Implementation | NIH | National Institute on Drug Abuse | 2023 to 2024 | $155,000 | August 15, 2023 | July 31, 2025 | EGAN, KATHLEEN LOUISE | reporter.nih.gov |
| Using electronic medical record (EMR) data to examine the impact of prenatal drug exposure: Evaluating availability, accuracy and utilty of exposure information | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $146,500 | August 25, 2022 | July 31, 2025 | BAILEY, BETH A | reporter.nih.gov |
| The role of Zhx2 in CYP2D regulation, oxycodone metabolism, and opioid addiction model behaviors. | NIH | National Institute on Drug Abuse | 2023 to 2024 | $96,668 | August 8, 2023 | July 31, 2026 | LYNCH, WILLIAM | reporter.nih.gov |
| Disentangling unique etiologies of prescription opioid misuse and heroin use: Analysis of longitudinal, twin, and genomic data | NIH | National Institute on Drug Abuse | 2021 to 2022 | $92,311 | August 1, 2021 | July 31, 2023 | DASH, GENEVIEVE FULLERTON | reporter.nih.gov |
| Drug-drug interactions between cannabis and hydrocodone. | NIH | National Institute on Drug Abuse | 2022 to 2024 | $77,985 | August 16, 2022 | August 17, 2024 | COATES, SHELBY | reporter.nih.gov |
| Drug-induced plasticity in mesolimbic dopamine circuits in opioid dependence | NIH | National Institute on Drug Abuse | 2021 to 2022 | $77,106 | September 1, 2020 | August 31, 2023 | GOODING, SARAH WARREN | reporter.nih.gov |
| Assessing the dose- and sex-dependent effects of oxytocin on opioid demand and reinstatement | NIH | National Institute on Drug Abuse | 2025 | $76,250 | December 15, 2024 | November 30, 2026 | SCHWENDT, MAREK | reporter.nih.gov |
| Bacteriophage virus-like particle based vaccines against oxycodone | NIH | National Institute on Drug Abuse | 2023 to 2024 | $75,468 | September 1, 2023 | August 31, 2025 | ROMANO, ISABELLA | reporter.nih.gov |
| Exploring Reactivity Among Patients with Chronic Pain Using Cannabis and Opioids: Mixed-Method Evidence of Promising Intervention Strategies | NIH | National Institute on Drug Abuse | 2024 | $73,828 | September 15, 2024 | September 14, 2026 | STONE, BRYANT MICHAEL | reporter.nih.gov |
| Oxytocin regulation of intravenous oxycodone demand: a role for nucleus accumbens | NIH | National Institute on Drug Abuse | 2023 to 2024 | $73,125 | May 16, 2023 | August 15, 2024 | WILKINSON, COURTNEY | reporter.nih.gov |
| Computational analysis of single-nucleus sequencing data for studying the cell type-specific basis of opioid use disorders | NIH | National Institute on Drug Abuse | 2022 to 2023 | $67,699 | April 1, 2022 | September 30, 2023 | ZHOU, JESSICA LU | reporter.nih.gov |
| Delta Opioid Receptor Regulation of Parvalbumin Interneuron Transmission and Oxycodone-Related Behavior | NIH | National Institute on Drug Abuse | 2025 | $49,538 | May 1, 2025 | April 30, 2028 | COLE, REBECCA | reporter.nih.gov |
| Evaluating the Multiscale Effects of Fentanyl-Induced Dependence and Abstinence within the Mouse Basolateral Amygdala | NIH | National Institute on Drug Abuse | 2025 | $45,982 | August 1, 2025 | July 31, 2028 | DESFOR, SHANE | reporter.nih.gov |
| Molecular target and circuitry underlying the preclinical effects of psychedelics in models of opioid use disorder | NIH | National Institute on Drug Abuse | 2023 | $39,388 | July 1, 2023 | May 10, 2024 | JASTER, ALAINA | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of Kentucky | Lexington, KY | 6 | $45.6 million | 0 | $0 |
| Ensysce Biosciences, Inc. | La Jolla, CA | 2 | $15.4 million | 0 | $0 |
| Sparian Biosciences, Inc. | New York City, NY | 1 | $13.7 million | 0 | $0 |
| University of Mississippi Med CTR | Jackson, MS | 7 | $10.9 million | 0 | $0 |
| Mclean Hospital | Belmont, MA | 5 | $10.7 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 8 | $9.9 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 6 | $9.4 million | 0 | $0 |
| Washington University | Saint Louis, MO | 6 | $9.2 million | 0 | $0 |
| University of Oregon Eugene | Eugene, OR | 1 | $9 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 4 | $8.4 million | 0 | $0 |
| Park Therapeutics, Inc. | Morristown, NJ | 1 | $6.7 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 6 | $6.6 million | 0 | $0 |
| University of Florida | Gainesville, FL | 7 | $6.4 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 1 | $6.4 million | 0 | $0 |
| Rand Corporation | Santa Monica, CA | 4 | $6.3 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 4 | $5.6 million | 0 | $0 |
| Stanford University | Stanford, CA | 6 | $5.6 million | 0 | $0 |
| Emory University | Atlanta, GA | 2 | $5.5 million | 0 | $0 |
| University of Washington | Seattle, WA | 5 | $5.5 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 4 | $5.3 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 3 | $5.2 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 3 | $5 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 4 | $4.9 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 2 | $4.8 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 3 | $4.6 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 3 | $4.6 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 2 | $4.5 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 4 | $4.5 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 2 | $4.4 million | 0 | $0 |
| Mebias Discovery, Inc. | Philadelphia, PA | 1 | $4.3 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 3 | $4.1 million | 0 | $0 |
| Ohio State University | Columbus, OH | 2 | $4.1 million | 0 | $0 |
| Yale University | New Haven, CT | 2 | $3.9 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 2 | $3.8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 2 | $3.6 million | 0 | $0 |
| New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC | New York, NY | 1 | $3.6 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 2 | $3.2 million | 0 | $0 |
| Amalgent Therapeutics, Inc. | Greenville, NC | 2 | $2.8 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 3 | $2.5 million | 0 | $0 |
| Epiodyne, Inc. | San Francisco, CA | 1 | $2.5 million | 0 | $0 |
| Arcato Laboratories, Inc. | Greenville, NC | 1 | $2.3 million | 0 | $0 |
| Altality, Inc. | Ann Arbor, MI | 2 | $2.1 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 2 | $2.1 million | 0 | $0 |
| BDH Pharma, LLC | Studio City, CA | 1 | $2.1 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 3 | $2.1 million | 0 | $0 |
| Revbio, Inc. | Lowell, MA | 1 | $2.1 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 1 | $2 million | 0 | $0 |
| University of New Mexico | Albuquerque, NM | 1 | $2 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 4 | $2 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 3 | $1.9 million | 0 | $0 |
| University of Chicago | Chicago, IL | 1 | $1.9 million | 0 | $0 |
| Quivive Pharma, INC | Rowland Heights, CA | 1 | $1.9 million | 0 | $0 |
| Wayne State University | Detroit, MI | 1 | $1.9 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 2 | $1.9 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 1 | $1.8 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 1 | $1.8 million | 0 | $0 |
| University of Colorado at Boulder | Boulder, CO | 1 | $1.8 million | 0 | $0 |
| Cog Analytics, LLC | Potomac, MD | 1 | $1.8 million | 0 | $0 |
| Florida International University | Miami, FL | 1 | $1.8 million | 0 | $0 |
| Base Pair Biotechnologies, Inc. | Pearland, TX | 1 | $1.8 million | 0 | $0 |
| Prevention Strategies, LLC | Greensboro, NC | 1 | $1.6 million | 0 | $0 |
| Indiana University | Bloomington, IN | 1 | $1.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 1 | $1.5 million | 0 | $0 |
| Marquette University | Milwaukee, WI | 2 | $1.5 million | 0 | $0 |
| Northeastern University | Boston, MA | 1 | $1.2 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 1 | $1.1 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 1 | $1.1 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 2 | $1 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 1 | $1 million | 0 | $0 |
| Rosalind Franklin Univ of Medicine & Sci | North Chicago, IL | 1 | $1 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 1 | $995,664 | 0 | $0 |
| Tamade, LLC | Pasadena, CA | 1 | $989,571 | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 1 | $956,514 | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 1 | $941,278 | 0 | $0 |
| Texas State University - San Marcos | San Marcos, TX | 1 | $939,705 | 0 | $0 |
| Duke University | Durham, NC | 2 | $914,390 | 0 | $0 |
| Rutgers Biomedical/health Sciences-Rbhs | New Brunswick, NJ | 2 | $784,424 | 0 | $0 |
| Baylor University | Waco, TX | 1 | $747,000 | 0 | $0 |
| California State University-Long Beach Foundation | Long Beach, CA | 1 | $672,656 | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 2 | $623,836 | 0 | $0 |
| Maryland Treatment Centers, Inc. | Baltimore, MD | 1 | $576,675 | 0 | $0 |
| University of Toronto | Toronto | 1 | $576,531 | 0 | $0 |
| University of South Carolina at Columbia | Columbia, SC | 2 | $573,847 | 0 | $0 |
| University of Connecticut | Storrs, CT | 1 | $571,335 | 0 | $0 |
| East Carolina University | Greenville, NC | 1 | $503,877 | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 1 | $489,697 | 0 | $0 |
| Oregon State University | Corvallis, OR | 1 | $483,221 | 0 | $0 |
| Southern California Univ of Health Scis | Whittier, CA | 1 | $459,595 | 0 | $0 |
| National Bureau of Economic Research Inc | Cambridge, MA | 1 | $438,703 | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 1 | $416,625 | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 1 | $415,340 | 0 | $0 |
| University of Arkansas | Fayetteville, AR | 1 | $412,363 | 0 | $0 |
| Northern Kentucky University | Highland Heights, KY | 1 | $411,000 | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 1 | $403,206 | 0 | $0 |
| Jillion Therapeutics Inc. | New York, NY | 1 | $399,884 | 0 | $0 |
| Chemregen INC | San Diego, CA | 1 | $399,536 | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 1 | $398,423 | 0 | $0 |
| Pillsmart Inc. | Brooklyn, NY | 1 | $379,072 | 0 | $0 |
| Baystate Medical Center, Inc. | Springfield, MA | 1 | $370,793 | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 1 | $369,930 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 73 | $38,920,178 | 0 | $0 |
| 2024 | 103 | $51,165,556 | 0 | $0 |
| 2023 | 124 | $80,662,085 | 0 | $0 |
| 2022 | 141 | $94,911,176 | 0 | $0 |
| 2021 | 101 | $91,688,186 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.